TY - JOUR
T1 - Adverse events and complications associated with intravitreal injection of anti-VEGF agents
T2 - A review of literature
AU - Falavarjani, K. Ghasemi
AU - Nguyen, Q. D.
N1 - Funding Information:
The University of Nebraska Medical Center, the employer of QDN, has received research funding from Genentech, Inc., Regeneron, Inc., and Abbott, Inc,. QDN has served on the Steering Committee for clinical trials sponsored by Genentech, Inc. and Regeneron, Inc. QDN has served on the Scientific Advisory Boards for Santen, Inc. and Bausch and Lomb, Inc. KGF has no conflict of interest.
PY - 2013/5/31
Y1 - 2013/5/31
N2 - Intravitreal injection of anti-vascular endothelial growth factor (VEGF) agents is increasingly used for the treatment of a wide variety of retinal diseases, including age-related macular degeneration, diabetic retinopathy and retinal vascular occlusions, and retinopathy of prematurity. Despite encouraging results in halting the disease and improving the vision, intravitreal injection of anti-VEGF agents may be associated with systemic adverse events and devastating ocular complications. In this review, we provide an overview of safety data for intravitreal injection of common anti-VEGF agents.
AB - Intravitreal injection of anti-vascular endothelial growth factor (VEGF) agents is increasingly used for the treatment of a wide variety of retinal diseases, including age-related macular degeneration, diabetic retinopathy and retinal vascular occlusions, and retinopathy of prematurity. Despite encouraging results in halting the disease and improving the vision, intravitreal injection of anti-VEGF agents may be associated with systemic adverse events and devastating ocular complications. In this review, we provide an overview of safety data for intravitreal injection of common anti-VEGF agents.
KW - Aflibercept
KW - Anti-vascular endothelial growth factor
KW - Bevacizumab
KW - Intravitreal injection
KW - Ranibizumab
KW - Safety
UR - http://www.scopus.com/inward/record.url?scp=84880268774&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84880268774&partnerID=8YFLogxK
U2 - 10.1038/eye.2013.107
DO - 10.1038/eye.2013.107
M3 - Review article
C2 - 23722722
AN - SCOPUS:84880268774
SN - 0950-222X
VL - 27
SP - 787
EP - 794
JO - Transactions of the Ophthalmological Societies of the United Kingdom
JF - Transactions of the Ophthalmological Societies of the United Kingdom
IS - 7
ER -